Compare IDEXX Laboratories, Inc. (IDXX) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs PubMatic Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while PubMatic Inc trades at $17.52 (market cap $804.41M). The key difference: IDEXX Laboratories, Inc. is far larger — about 57.5× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | PUBM | |
|---|---|---|
Market Cap | $46.22B | $804.41M |
Sector | Health | Technology |
52-Week High | $766.68 | $17.78 |
52-Week Low | $526.44 | $6.28 |
Enterprise Value | $47.12B | $707.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
PUBM trades at $17.18, down 3.27% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported a Q2 2026 earnings beat with 11% revenue growth, driven by mobile app and CTV segments, though it remains unprofitable with a negative net income margin. Recent news highlights strategic hires and product launches like AgenticOS to capitalize on AI in advertising.
The outlook is mixed: strong revenue growth and analyst buy ratings support upside to the $20.83 consensus target, but profitability challenges and high valuation ratios pose risks. Investors should weigh the growth potential in high-margin segments against persistent losses and competitive pressures in the ad tech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
